REL-1017: A New Treatment in the Works for Depression

Relmada Therapeutics just completed their phase II adjunctive major depressive disorder trial for their new medication dextromethadone (REL-1017), where they observed statistically significant anti-depressant effects, a favorable safety profile, and favorable tolerability. Maurizio Fava, MD, discusses the results and need-to-know information for REL-1017.

Dr Fava is chief of psychiatry at Massachusetts General Hospital and director of the division of clinical research for Massachusetts General Research Institute.